Neurofilament light chain predicts disease activity in relapsing-remitting MS

Compare serum free light chain (sFLC) and involved (monoclonal) FLC (iFLC) in serum vs urine protein electrophoresis (UPEP) as a diagnostic disease marker in light-chain

Conclusion: Our study provides evidence for proteomic differences in T cells from relapsing–remitting MS patients compared to healthy controls and also identifies dysregulation

15 Thus, we con- ducted the Supplementation of Vigantol Oil versus Placebo Add-on in Patients with Relapsing-Remitting MS (RRMS) Receiving Rebif Treatment (SOLAR) study to

Serum levels of 25-hydroxyvi- tamin D are a biomarker of future disease activity in patients with early relapsing–remitting multiple sclerosis (RRMS), and vitamin D supplementation

Based on the available evidence and the meta-analysis used: alemtuzumab is most likely to be the best treatment with respect to annual relapse rate; ocrelizumab and alemtuzumab

To chart the vitamin E levels and their relationship to disease activity in Norwegian MS patients, we have measured alpha-tocopherol in serum samples from 88 relapsing-remitting

Association between Serum neuro fi lament light chain levels and long-term disease course Among patients With multiple sclerosis followed up for

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing remitting multiple sclerosis: a randomised controlled phase 3 trial. Coles AJ, Twyman CL,